Role of Interleukin-13 Pathways on Pain and Itch Sensitivity
ConditionItch
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorAalborg University
About this trial
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.
Eligibility criteria
Qualifiers
Healthy men and women
18-60 years
Disqualifiers
Pregnancy or lactation
Drug addiction defined as any use of cannabis, opioids, or other drugs
Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)
Moles, wounds, scars, or tattoos in the area to be treated or tested
Trial design
Treatments tested in this trial
- Histamine
- Cowhage
- bovine adrenal medulla (BAM8-22)
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov